You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Radiolabeled Somatostatin Antagonists

Showing 1 - 25 of 1,150
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Neuroendocrine Tumors Trial in New York (PET/CT Imaging, 68Ga-DOTA-JR11, 177Lu-DOTA-JR11)

Completed
Has Results
  • Neuroendocrine Tumors
  • PET/CT Imaging
  • +2 more
  • New York, New York
    Memorial Sloan Kettering Cancer Center
Jan 3, 2022

Neuroendocrine Tumors, Liver-Dominant Metastatic Pancreatic Neuroendocrine Tumors Trial in New York (177Lu-DOTATATE)

Recruiting
  • Neuroendocrine Tumors
  • Liver-Dominant Metastatic Pancreatic Neuroendocrine Tumors
  • New York, New York
    Memorial Sloan Kettering Cancer Center
Jan 19, 2023

Nasopharyngeal Carcinoma Trial in Xiamen (177Lu-EB-LM3 1, 177Lu-EB-LM3 2)

Recruiting
  • SSTR2-positive Tumors
  • 177Lu-LNC1010 1
  • +2 more
  • Xiamen, China
    The First Affiliated Hospital of Xiamen University
Nov 20, 2022

Neuroendocrine Tumors Trial in Innsbruck, Kraków, Ljubljana ([99mTc]Tc-TECANT1)

Recruiting
  • Neuroendocrine Tumors
  • Innsbruck, Austria
  • +2 more
May 12, 2023

Neuroendocrine Tumors Trial in Beijing (68Ga-NODAGA-LM3 and 68Ga-DOTA-LM3 PET/CT, 68Ga-NODAGA-LM3 and 68Ga-NODAGA-JR11 PET/CT)

Recruiting
  • Neuroendocrine Tumors
  • 68Ga-NODAGA-LM3 and 68Ga-DOTA-LM3 PET/CT
  • 68Ga-NODAGA-LM3 and 68Ga-NODAGA-JR11 PET/CT
  • Beijing, Beijing, China
    Peking Union Medical College Hospital
Nov 3, 2020

Neuroendocrine Tumors Trial in Beijing (Al18F-NOTA-LM3, 68Ga-DOTATATE, 68Ga-NODAGA-LM3)

Recruiting
  • Neuroendocrine Tumors
  • Al18F-NOTA-LM3
  • +2 more
  • Beijing, China
    Peking Union Medical College Hospital
Sep 20, 2023

Neuroendocrine Tumor, Liver Metastases, Neuroendocrine Gastroenteropancreatic Tumour Trial in France (Positron emission

Recruiting
  • Neuroendocrine Tumor
  • +2 more
  • Positron emission tomography computed tomography (PET/CT) with Intra-hepatic (IAH) injection
  • +3 more
  • Bordeaux, France
  • +3 more
Nov 18, 2021

Hybrid PET/MR and PET/CT in Neuroendocrine Diseases and Tumor

Recruiting
  • PET / CT
  • +3 more
  • 68Ga-DOTA-TATE PET/MR and PET/CT imaging
  • Wuhan, Hubei, China
    China, Hubei Province
Apr 26, 2022

SCLC,Extensive Stage Trial in Omaha (RYZ101 Dose Level 1, RYZ101 Dose Level 2, RYZ101 Dose Level 3)

Recruiting
  • SCLC,Extensive Stage
  • RYZ101 Dose Level 1
  • +6 more
  • Omaha, Nebraska
    Nebraska Cancer Specialists
Nov 18, 2022

High Grade Glioma, Meningioma, Embryonal Tumor Trial in United States (LUTATHERA® (Lutetium Lu 177 dotatate))

Recruiting
  • High Grade Glioma
  • +12 more
  • LUTATHERA® (Lutetium Lu 177 dotatate)
  • Aurora, Colorado
  • +8 more
Jan 16, 2023

GEP-NET, Gastroenteropancreatic Neuroendocrine Tumor, Gastroenteropancreatic Neuroendocrine Tumor Disease Trial in United States

Recruiting
  • GEP-NET
  • +6 more
  • Duarte, California
  • +3 more
Jul 28, 2022

Neuroendocrine Tumors Trial in Houston (AlphaMedix)

Recruiting
  • Neuroendocrine Tumors
  • Houston, Texas
    Excel Diagnostics and Nuclear Oncology Center
Jan 5, 2022

Neuroendocrine Carcinoma Trial in London (Lu-DOTA-TATE)

Active, not recruiting
  • Neuroendocrine Carcinoma
  • Lu-DOTA-TATE
  • London, Ontario, Canada
    London Health Sciences Centre
Apr 5, 2022

Meningioma Trial in Vandœuvre-lès-Nancy (Everolimus)

Not yet recruiting
  • Meningioma
  • Vandœuvre-lès-Nancy, Grand Est, France
  • +1 more
Nov 8, 2023

Neuroendocrine Tumors Trial in Beijing (Gallium-68 NODAGA-LM3 PET/CT, Gallium-68 DOTA-LM3 PET/CT, Gallium-68 DOTATATE PET/CT)

Completed
  • Neuroendocrine Tumors
  • Gallium-68 NODAGA-LM3 PET/CT
  • +2 more
  • Beijing, Beijing, China
    Peking Union Medical College Hospital
Dec 20, 2021

Non-variceal Gastrointestinal Bleeding Trial in Cairo (PPI group, PPI plus octreotide)

Recruiting
  • Non-variceal Gastrointestinal Bleeding
  • PPI group
  • PPI plus octreotide
  • Cairo, Egypt
    NHTMRI
Sep 28, 2023

Healthy Trial in Copenhagen, Hvidovre (Proton Pump inhibitor, Placebo)

Recruiting
  • Healthy
  • Proton Pump inhibitor
  • Placebo
  • Copenhagen, Capital, Denmark
  • +1 more
Nov 1, 2023

Locally Advanced Neuroendocrine Tumor, Metastatic Neuroendocrine Tumor Trial in Houston (Placebo Administration, Questionnaire

Recruiting
  • Locally Advanced Neuroendocrine Neoplasm
  • Metastatic Neuroendocrine Neoplasm
  • Placebo Administration
  • +2 more
  • Houston, Texas
    M D Anderson Cancer Center
Jan 31, 2023

Nasopharyngeal Cancer, Epstein-Barr Virus Related Carcinoma Trial in Singapore (FDG-PET, Galium-68 DOTATATE)

Recruiting
  • Nasopharyngeal Cancer
  • Epstein-Barr Virus Related Carcinoma
  • FDG-PET
  • Galium-68 DOTATATE
  • Singapore, Singapore
    National Cancer Centre Singapore
Oct 13, 2022

Somatostatin Receptors and GH Receptor Expression on Bone of

Completed
  • Evaluation of the Expression of Somatostatin Receptors and GH Receptor on Bone of Acromegalic Patients
  • Trans-sphenoidal surgery
  • Roma, Italy
    Fondazione Policlinnico Gemelli IRCCS
Apr 6, 2023

Neuroendocrine Tumors Trial in Portland (Cabozantinib, Lu-177)

Not yet recruiting
  • Neuroendocrine Tumors
  • Portland, Oregon
    Providence Portland Cancer Institute - Franz Clinic
Feb 10, 2022

Neuroendocrine Tumors, Carcinoid Tumors, Neuroblastoma Trial in Iowa City (68Ga-DOTATOC PET/CT)

Completed
Has Results
  • Neuroendocrine Tumors
  • +3 more
  • 68Ga-DOTATOC PET/CT
  • Iowa City, Iowa
    University of Iowa Health Care
Jul 24, 2021

Meningioma Trial in Basel (177Lu-DOTA-JR11 (Phase 0); Cycle 1 and Cycle 2 (cross-over), 177Lu-DOTATOC (Phase 0); Cycle 1 and

Recruiting
  • Meningioma
  • 177Lu-DOTA-JR11 (Phase 0); Cycle 1 and Cycle 2 (cross-over)
  • +2 more
  • Basel, Basel-Stadt, Switzerland
    University Hospital Basel, Department of Neurosurgery
Aug 2, 2021

Neuroendocrine Neoplasia's (NENs), Gastroenteropancreatic Neuroendocrine Tumour (GEP-NET) Trial in Basel (161Tb-DOTA-LM3,

Not yet recruiting
  • Neuroendocrine Neoplasia's (NENs)
  • Gastroenteropancreatic Neuroendocrine Tumour (GEP-NET)
  • Basel, Switzerland
    Division of Nuclear Medicine, University Hospital Basel
Apr 27, 2022

Ovarian Cancer Trial in New York (90Y-hu3S193, 111In-hu3S193)

Completed
Has Results
  • Ovarian Cancer
  • 90Y-hu3S193
  • 111In-hu3S193
  • New York, New York
    Memorial Sloan-Kettering Cancer Center
Oct 3, 2022